Sylatron Dosage
Generic name: peginterferon alfa-2b 40ug in 0.1mL;
Dosage form: injection
Drug classes: Antineoplastic interferons, Antiviral interferons
Medically reviewed by Drugs.com. Last updated on Oct 23, 2023.
Recommended Dosing
- The recommended starting dose is 6 mcg/kg/week subcutaneously for 8 doses, followed by 3 mcg/kg/week subcutaneously for up to 5 years.
- Premedicate with acetaminophen 500 to 1000 mg orally 30 minutes prior to the first dose of SYLATRON and as needed for subsequent doses.
- The recommended starting doses of SYLATRON in patients with moderate or severe renal impairment or end-stage renal disease (ESRD) are listed in Table 1. No dose adjustment is needed for patients with a creatinine clearance (CLcr) > 50 mL/min/1.73m2.
Degree of Renal Impairment | Creatinine Clearance (mL/min/1.73m2) | Initial doses for 8 weeks | Follow-up doses for 5 years |
---|---|---|---|
Moderate | 30 – 50 | 4.5 mcg/kg/week | 2.25 mcg/kg/week |
Severe | <30 | 3 mcg/kg/week | 1.5 mcg/kg/week |
End-Stage Renal Disease | On dialysis | 3 mcg/kg/week | 1.5 mcg/kg/week |
Dose Modification Guidelines
Guidelines for Dose Modification provided below are based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE Version 2.0).
- Permanently discontinue SYLATRON for:
- Persistent or worsening severe neuropsychiatric disorders
- Grade 4 non-hematologic toxicity
- Inability to tolerate a dose of 1 mcg/kg/wk
- New or worsening retinopathy
- Withhold SYLATRON dose for any of the following:
- Absolute Neutrophil Count (ANC) less than 0.5×109/L
- Platelet Count (PLT) less than 50×109/L
- ECOG PS greater than or equal to 2
- Non-hematologic toxicity greater than or equal to Grade 3
- Resume dosing at a reduced dose (see Table 1) when all of the following are present:
- Absolute Neutrophil Count (ANC) greater than or equal to 0.5×109/L
- Platelet Count (PLT) greater than or equal to 50×109/L
- ECOG PS 0-1
- Non-hematologic toxicity has completely resolved or improved to Grade 1
Starting Dose | Dose Modifications for Doses 1 to 8 |
---|---|
6 mcg/kg/week | First Dose Modification: 3 mcg/kg/week |
Second Dose Modification: 2 mcg/kg/week | |
Third Dose Modification: 1 mcg/kg/week | |
Permanently discontinue if unable to tolerate 1 mcg/kg/week | |
Starting Dose | Dose Modifications for Doses 9 to 260 |
3 mcg/kg/week | First Dose Modification: 2 mcg/kg/week |
Second Dose Modification: 1 mcg/kg/week | |
Permanently discontinue if unable to tolerate 1 mcg/kg/week |
Preparation and Administration
Reconstitute SYLATRON with 0.7 mL of Sterile Water for Injection, USP. The Sterile Water for Injection supplied contains 5 mL. Each vial of Sterile Water for Injection is intended for single dose. Discard any unused Sterile Water for Injection, USP.
SYLATRON Single-Dose Vial | Diluent (Sterile Water for Injection, USP) | Deliverable Product and Volume | Final Concentration | ||
---|---|---|---|---|---|
200 mcg* | add | 0.7 mL | = | 200 mcg in 0.5 mL | 40 mcg/0.1 mL |
300 mcg† | add | 0.7 mL | = | 300 mcg in 0.5 mL | 60 mcg/0.1 mL |
600 mcg‡ | add | 0.7 mL | = | 600 mcg in 0.5 mL | 120 mcg/0.1 mL |
- Swirl gently to dissolve the lyophilized powder. DO NOT SHAKE.
- Visually inspect the solution for particulate matter and discoloration prior to administration. Discard if solution is discolored, cloudy, or if particulates are present.
- Do not withdraw more than 0.5 mL of reconstituted solution from each vial.
- Administer SYLATRON subcutaneously. Rotate injection sites.
- If reconstituted solution is not used immediately, store at 2°-8°C (36°-46°F) for no more than 24 hours. Discard reconstituted solution after 24 hours. DO NOT FREEZE.
- For single-dose only. DISCARD ANY UNUSED PORTION.
More about Sylatron (peginterferon alfa-2b)
- Check interactions
- Compare alternatives
- Side effects
- During pregnancy
- FDA approval history
- Drug class: antineoplastic interferons
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.